BOSTON, October 19, 2020: BOSTON, October DAY, 2020: Morgan Lewis advised BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, in the company’s definitive agreement to be acquired by global specialty pharmaceutical company Endo International plc. The all-cash transaction totals $658 million in equity value.
Partners Carl Valenstein, Celia Soehner, and Sean Donahue, of counsel Jeff Letalien, and associates Ben Stein, Ali Good, Fannie Law, and Kira Schwartz represented BioSpecifics.